一个早就该正视的问题,终于被推到了所有人面前:2025年了,减肥药公司到底该值多少钱?过去两年,减肥药是全球医药赛道的“顶流”。第一代GLP-1药物的竞争如火如荼之际,全球大小药企更是早已围绕下一代减肥药展开军备竞赛。这其中,口服小分子减肥药凭借药物成本、依从性等优势,更是被抢疯了。去年底,默沙东宣布,引进翰森制药一款临床前口服小分子GLP-1,就支付了1.12亿美元首付款,里程碑款最高可达19...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.